Guidelines for Review of GYN Cytology Samples in the Context of Investigations

The Pap test is the most effective cancer-screening test in medical history and remains the most effective screening method for the identification of pre-malignant cervicovaginal conditions. The Pap test has been associated with a 70% or greater decrease in the United States death rate from cervical cancer.

If the Pap test is to continue as an effective cancer-screening procedure, it must remain widely accessible and reasonably priced for all women, including those economically disadvantaged and at high risk for cervical cancer. The inherent limitations of this screening test call for an objective and scientific method for review of questioned cases. This systematic review process must be fair and objective to the patient and to the laboratory.

The impetus behind these guidelines is to ensure that professional witnesses provide testimony that is impartial. They are intended to promote qualifying standards for all medical witnesses. These guidelines can be used to show that the investigation is consistent with current professional recommendations. The evidence-based professional practices recommended in these principles are directed to all expert witnesses, both defense and plaintiff consultants, with the recognition that these guidelines are non-binding.

The Pap test is a screening test that involves subjective interpretation by a cytotechnologist or pathologist of the thousands of cells that are present on a typical GYN cytology sample. Experience indicates an irreducible false-negative rate. Although rescreening can reduce the false-negative rate, zero-error performance cannot currently be attained. Many factors, including the subjectivity involved in interpreting difficult cases and sampling problems with specimen collection, prevent zero-error performance.

The following guidelines should be used for review of GYN cytology samples in the context of official investigations in order to increase neutrality in evaluations:

1. The finding of a false-negative sample is not necessarily evidence of practice below the standard of care. The decision as to whether a false-negative GYN cytology sample is the result of negligence should be made not only on the basis of evaluation of a single sample but should also include an evaluation of the patient’s past clinical history and previous GYN cytology results. The test results should also be viewed in the context of the accredited laboratory’s overall performance on GYN cytology samples.
2. Equivocal interpretive categories including atypical squamous cells (ASC) and atypical glandular cells (AGC) have poor inter- and intra-observer reproducibility. Therefore, most cases of ASC and AGC do not represent consistently identifiable abnormalities and a reasonable basis for allegations of practice below a reasonable prudent practitioner standard of care.

3. Pap test slides being assessed for an objective unbiased basis on which to assert a violation of a reasonable prudent practitioner standard of practice should first be reviewed without knowledge of clinical outcome and in an environment that simulates the normal screening practice. A violation of a reasonable prudent practitioner standard of practice based on how specific Pap tests were screened and interpreted can ideally only be established through an unbiased blinded rescreening review process that includes the contested case as one of a number of normal and abnormal GYN cytology samples representing a variety of disease states. Focused review or review with knowledge of subsequent development of carcinoma inevitably biases the objectivity of the review and does not reflect standard practice. If data is available, for slides that have been pre-screened with computer assistance, the original fields of view (FOV) should be reviewed by the expert witness to ensure that abnormal cells are present in the FOV which would prompt a full manual review.

4. The standard of care should be that of the reasonable and prudent practitioner. Courts and experts should recognize that a false-negative result by itself is not sufficient proof of negligence. Rather, the courts should evaluate whether the overall Pap test practices of the laboratory meet the standard of care and whether unbiased blinded rescreening consistently detects significant abnormalities not initially identified by the laboratory.

5. With the recognition that it is the court’s prerogative to determine expert’s qualifications, we recommend that professional expert witnesses who do not have significant practical experience in Cytopathology should not be qualified to express an expert opinion on the standard of care. Instead, a court should rely upon the testimony of expert physician-witnesses who have, at a minimum, the following qualifications:

- Maintains a current and unrestricted license to practice medicine in the state where he/she is practicing.
- Certified by the appropriate A.B.M.S. specialty or subspecialty board, and is fully trained in the practice of Cytopathology; and
- Knowledgeable in the practice of Cytopathology as indicated by years of practice experience, current up-to-date continuing medical education, active engagement in the practice of Cytopathology, and experience with the cytologic preparation method used for the case in question.
Alternatively, to adjudicate the performance of cytotechnologists, the court may rely
upon the testimony of expert cytotechnologist witnesses who have, at a minimum, the
following qualifications:

- Maintains a current and unrestricted license to practice cytotechnology in
  his/her state if this is a state requirement.
- Certified as a cytotechnologist by the ASCP Board of Certification, and fully
  trained in the practice of cytopathology; and
- Knowledgeable in the practice of cytotechnology as indicated by years of
  experience, current up-to-date continuing education, active engagement in the
  practice of cytotechnology, and experience with the cytologic preparation
  method used for the case in question.

6. Compensation of the expert witness should reasonably reflect the time and effort
   expended by the witness in preparation, depositions, and trial. Compensation of an
   expert witness contingent on the outcome of the case introduces the possibility of bias
   and should not be permitted.

7. Where disputes about false negatives or mis-reads arise, the practitioner should also
   strongly consider alternative dispute resolution mechanisms, including mediation or
   non-binding arbitration by a panel of individuals trained and having experience in
   Cytopathology before proceeding with civil litigation relating to a Pap test. Such panels
   could be developed through national societies with interest and experience in GYN
   cytology.

Approved by the ASC Executive Board on May 3, 2015

References:
- Renshaw A, Henry M, Howell L, Nayar R for the ASC. Review and Update of the Guidelines for
  Review of Gynecologic Cytology in the Course of Litigation. JASC 2014, 3, I-IV
- Michael Goldrich, MD; Medical Testimony. Reference Committee on Amendments to
  A-04.